GeoffreyGuyEmersonMDPhD

Retinal Disease

Chief of Staff, Phillips Eye Institute

Dr. Emerson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
710 E 24th St
Ste 304
Minneapolis, MN 55404
Phone+1 612-871-2292

Fax+1 952-460-5274

Oregon Health & Science UniversityFellowship, Surgical Retina and Vitreous, 2005 - 2007
Johns Hopkins UniversityResidency, Ophthalmology, 2002 - 2005
Yale-New Haven Medical CenterInternship, Internal Medicine, 2001 - 2002
Yale School of MedicineClass of 2001

CMS Meaningful Use Stage 1 Certification IntelleChart EHR, MDIntelleSys, LLC, 2013
Fellow (FAAO) American Academy of Ophthalmology

PubMed

So Many Injections, So Much Waste: Understanding the Environmental Impact of Intravitreal Injections.
Jacob D Grodsky, Emily M Schehlein, David F Chang, Nimesh A Patel, Nathan L Scott
Journal of Vitreoretinal Diseases. 2024-12-25
1 citations
BILATERAL EYE PATCHING MAY IMPROVE CLINICAL OUTCOMES FOR ACUTE PRIMARY RHEGMATOGENOUS RETINAL DETACHMENT.
Peter H Tang, Christian D Curran, Ali R Salman, Guneet S Sodhi, Tommaso Vagaggini
Retina. 2024-04-01
Anti-complement drugs for the treatment of geographic atrophy and the release of silicone oil.
Gustavo Barreto Melo, Geoffrey Guy Emerson
International Journal of Retina and Vitreous. 2024-01-05

The Connection of Board Certification and Risk of Endophthalmitis After Intravitreal InjectionOctober 2021

Effect of Initial Management with Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss Among Patients with Diabetic Macular Edema Involving the Center of the Macula and Good Visual AcuityMay 1st, 2019